Millennium Management LLC Buys 44,449 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Millennium Management LLC raised its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 10.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 457,014 shares of the biopharmaceutical company's stock after purchasing an additional 44,449 shares during the quarter. Millennium Management LLC owned 0.15% of Amicus Therapeutics worth $4,305,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also bought and sold shares of the company. HealthInvest Partners AB lifted its position in Amicus Therapeutics by 18.6% during the fourth quarter. HealthInvest Partners AB now owns 326,840 shares of the biopharmaceutical company's stock valued at $3,076,000 after purchasing an additional 51,368 shares during the last quarter. Tempus Wealth Planning LLC bought a new stake in Amicus Therapeutics during the fourth quarter valued at approximately $259,000. Intech Investment Management LLC lifted its position in Amicus Therapeutics by 59.7% during the fourth quarter. Intech Investment Management LLC now owns 124,704 shares of the biopharmaceutical company's stock valued at $1,175,000 after purchasing an additional 46,633 shares during the last quarter. Norges Bank bought a new stake in Amicus Therapeutics during the fourth quarter valued at approximately $29,033,000. Finally, Renaissance Technologies LLC lifted its position in Amicus Therapeutics by 174.1% during the fourth quarter. Renaissance Technologies LLC now owns 2,108,616 shares of the biopharmaceutical company's stock valued at $19,863,000 after purchasing an additional 1,339,316 shares during the last quarter.

Amicus Therapeutics Trading Up 1.6%

NASDAQ:FOLD traded up $0.10 during midday trading on Tuesday, reaching $6.26. 5,044,090 shares of the stock traded hands, compared to its average volume of 2,900,631. The company has a fifty day moving average of $6.74 and a 200 day moving average of $8.52. Amicus Therapeutics, Inc. has a 12 month low of $5.81 and a 12 month high of $12.65. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39. The stock has a market capitalization of $1.93 billion, a P/E ratio of -34.78, a PEG ratio of 1.51 and a beta of 0.64.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on FOLD shares. Wells Fargo & Company dropped their target price on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a research report on Thursday, February 20th. UBS Group lifted their target price on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. The Goldman Sachs Group cut their price objective on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research note on Friday, May 2nd. Needham & Company LLC reaffirmed a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Finally, Wall Street Zen cut shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $16.22.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.